Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?
Identifieur interne : 000362 ( PubMed/Corpus ); précédent : 000361; suivant : 000363Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?
Auteurs : Ana Marques ; Maria Livia Fantini ; Dominique Morand ; Bruno Pereira ; Philippe Derost ; Miguel Ulla ; Bérengère Debilly ; Jean-Jacques Lemaire ; Franck DurifSource :
- Sleep medicine [ 1878-5506 ] ; 2015.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Deep Brain Stimulation (adverse effects), Deep Brain Stimulation (methods), Dopaminergic Neurons (drug effects), Dopaminergic Neurons (physiology), Female, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (therapy), Prospective Studies, Restless Legs Syndrome (etiology), Subthalamic Nucleus (drug effects), Subthalamic Nucleus (physiopathology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- adverse effects : Deep Brain Stimulation.
- drug effects : Dopaminergic Neurons, Subthalamic Nucleus.
- drug therapy : Parkinson Disease.
- etiology : Restless Legs Syndrome.
- methods : Deep Brain Stimulation.
- physiology : Dopaminergic Neurons.
- physiopathology : Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Prospective Studies.
Abstract
Studies investigating the effects of subthalamic deep-brain stimulation (DBS-STN) on restless legs syndrome (RLS) in Parkinson's disease (PD) are limited and report conflicting results, with some describing the emergence of RLS after DBS-STN, while others report postoperative improvement of this disorder. Severe decrease in postoperative dopaminergic medications dose, which may unmask RLS symptoms, has been proposed to explain the emergence of RLS after surgery. We aimed to specifically identify factors associated with the risk of developing RLS after DBS-STN in order to enhance our comprehension of the underlying mechanisms contributing to the development of RLS in PD.
DOI: 10.1016/j.sleep.2014.11.020
PubMed: 25881920
Links to Exploration step
pubmed:25881920Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?</title><author><name sortKey="Marques, Ana" sort="Marques, Ana" uniqKey="Marques A" first="Ana" last="Marques">Ana Marques</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France. Electronic address: ar_marques@chu-clermontferrand.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Fantini, Maria Livia" sort="Fantini, Maria Livia" uniqKey="Fantini M" first="Maria Livia" last="Fantini">Maria Livia Fantini</name><affiliation><nlm:affiliation>UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Morand, Dominique" sort="Morand, Dominique" uniqKey="Morand D" first="Dominique" last="Morand">Dominique Morand</name><affiliation><nlm:affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pereira, Bruno" sort="Pereira, Bruno" uniqKey="Pereira B" first="Bruno" last="Pereira">Bruno Pereira</name><affiliation><nlm:affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derost, Philippe" sort="Derost, Philippe" uniqKey="Derost P" first="Philippe" last="Derost">Philippe Derost</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Debilly, Berengere" sort="Debilly, Berengere" uniqKey="Debilly B" first="Bérengère" last="Debilly">Bérengère Debilly</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lemaire, Jean Jacques" sort="Lemaire, Jean Jacques" uniqKey="Lemaire J" first="Jean-Jacques" last="Lemaire">Jean-Jacques Lemaire</name><affiliation><nlm:affiliation>Neurosurgery Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25881920</idno><idno type="pmid">25881920</idno><idno type="doi">10.1016/j.sleep.2014.11.020</idno><idno type="wicri:Area/PubMed/Corpus">000362</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000362</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?</title><author><name sortKey="Marques, Ana" sort="Marques, Ana" uniqKey="Marques A" first="Ana" last="Marques">Ana Marques</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France. Electronic address: ar_marques@chu-clermontferrand.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Fantini, Maria Livia" sort="Fantini, Maria Livia" uniqKey="Fantini M" first="Maria Livia" last="Fantini">Maria Livia Fantini</name><affiliation><nlm:affiliation>UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Morand, Dominique" sort="Morand, Dominique" uniqKey="Morand D" first="Dominique" last="Morand">Dominique Morand</name><affiliation><nlm:affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pereira, Bruno" sort="Pereira, Bruno" uniqKey="Pereira B" first="Bruno" last="Pereira">Bruno Pereira</name><affiliation><nlm:affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derost, Philippe" sort="Derost, Philippe" uniqKey="Derost P" first="Philippe" last="Derost">Philippe Derost</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Debilly, Berengere" sort="Debilly, Berengere" uniqKey="Debilly B" first="Bérengère" last="Debilly">Bérengère Debilly</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lemaire, Jean Jacques" sort="Lemaire, Jean Jacques" uniqKey="Lemaire J" first="Jean-Jacques" last="Lemaire">Jean-Jacques Lemaire</name><affiliation><nlm:affiliation>Neurosurgery Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><nlm:affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Sleep medicine</title><idno type="eISSN">1878-5506</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Deep Brain Stimulation (adverse effects)</term><term>Deep Brain Stimulation (methods)</term><term>Dopaminergic Neurons (drug effects)</term><term>Dopaminergic Neurons (physiology)</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (therapy)</term><term>Prospective Studies</term><term>Restless Legs Syndrome (etiology)</term><term>Subthalamic Nucleus (drug effects)</term><term>Subthalamic Nucleus (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Dopaminergic Neurons</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dopaminergic Neurons</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies investigating the effects of subthalamic deep-brain stimulation (DBS-STN) on restless legs syndrome (RLS) in Parkinson's disease (PD) are limited and report conflicting results, with some describing the emergence of RLS after DBS-STN, while others report postoperative improvement of this disorder. Severe decrease in postoperative dopaminergic medications dose, which may unmask RLS symptoms, has been proposed to explain the emergence of RLS after surgery. We aimed to specifically identify factors associated with the risk of developing RLS after DBS-STN in order to enhance our comprehension of the underlying mechanisms contributing to the development of RLS in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25881920</PMID><DateCreated><Year>2015</Year><Month>05</Month><Day>08</Day></DateCreated><DateCompleted><Year>2016</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5506</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Sleep medicine</Title><ISOAbbreviation>Sleep Med.</ISOAbbreviation></Journal><ArticleTitle>Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?</ArticleTitle><Pagination><MedlinePgn>583-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sleep.2014.11.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1389-9457(15)00093-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Studies investigating the effects of subthalamic deep-brain stimulation (DBS-STN) on restless legs syndrome (RLS) in Parkinson's disease (PD) are limited and report conflicting results, with some describing the emergence of RLS after DBS-STN, while others report postoperative improvement of this disorder. Severe decrease in postoperative dopaminergic medications dose, which may unmask RLS symptoms, has been proposed to explain the emergence of RLS after surgery. We aimed to specifically identify factors associated with the risk of developing RLS after DBS-STN in order to enhance our comprehension of the underlying mechanisms contributing to the development of RLS in PD.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">In this observational prospective study, we evaluated the occurrence of RLS in 31 patients with PD originally free from RLS symptoms, six months after bilateral chronic DBS-STN, and compared clinical and treatment parameters of patients who developed postoperative RLS with those of patients without postoperative RLS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Six patients out of 31 reported post-operative emergence of RLS. There was no between-group difference in demographic data, pre-operative treatment parameters or clinical improvement measures after DBS-STN. However, PD patients with emergence of RLS after DBS-STN had a higher dose of dopamine agonists at postoperative evaluation compared to PD patients without emergence of RLS (p = 0.040) and a lower percentage of decrease in dopamine agonists (p = 0.043).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overstimulation resulting from cumulative effects of dopamine agonists and STN-DBS may induce changes in excitability of the dopaminergic system, leading to an emergence of RLS. Clinicians should take into account this phenomenon while adjusting pharmacological treatment after surgery.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France. Electronic address: ar_marques@chu-clermontferrand.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fantini</LastName><ForeName>Maria Livia</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Délégation à la Recherche Clinique et à l'Innovation DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derost</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulla</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debilly</LastName><ForeName>Bérengère</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaire</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Neurosurgery Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Clermont-Ferrand, F-63001 Clermont-Ferrand, France; UFR Medicine, University Clermont 1, EA 7280, F-63001 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sleep Med</MedlineTA><NlmUniqueID>100898759</NlmUniqueID><ISSNLinking>1389-9457</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012148" MajorTopicYN="N">Restless Legs Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep brain stimulation</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Restless legs syndrome</Keyword><Keyword MajorTopicYN="N">Subthalamic nucleus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25881920</ArticleId><ArticleId IdType="pii">S1389-9457(15)00093-3</ArticleId><ArticleId IdType="doi">10.1016/j.sleep.2014.11.020</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000362 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000362 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25881920
|texte= Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25881920" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |